24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation

Twenty-four-hour heart rate control by verapamil given as conventional tablets t.d.s., or as a new slow release formulation once daily, has been compared in an open cross-over trial. Eight patients with chronic atrial fibrillation and one with chronic atrial flutter were studied outside hospital.